Drug Trial Radar · NCT05689645
F573 for Injection for the Treatment of Liver Injury/Failure
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
97
Planned (sponsor's estimate)
Start
Mar 24, 2023
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).
Conditions
- Acute Liver Failure
- Acute-On-Chronic Liver Failure
Interventions
F573 for injectionDrug
The first stage:the first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg, and the subsequent 9 patients with CHB were given doses of 2.0 mg/kg, with an administration volume of 2 mL and intramuscular injection (IM) according to the efficacy and safety test results of the first 16 patients. The dose was given once a day for 7 days and calculated according to the weight of the last visit. The second stage:According to the results of Phase I efficacy and safety trials, the dosage was determined to be 0.5 mg/kg and 2.0 mg/kg, the dosage volume was 2 mL, intramuscular injection (IM), once a day for 14 days, and the dosage was calculated according to the weight of the latest visit. The third stage:The dosage was determined according to the results of the first and second phase efficacy and safety trials. The dosage volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days, and the dosage was calculated according to the weight of the latest .
Sterilizing water for injectionDrug
The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection. Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AE), serious adverse events (SAE)Time frame: 7 days of administration in the first stage and 14 days of administration in the second stage
- Adverse events (AE), serious adverse events (SAE)Time frame: followed up for 28 days in the first stage and followed up for 14 days in the second stage
- clinical laboratory tests :blood routineTime frame: 7 days of administration in the first stage and 14 days of administration in the second stage
- clinical laboratory tests :blood routineTime frame: followed up for 28 days in the first stage and followed up for 14 days in the second stage
- clinical laboratory tests :blood biochemistryTime frame: 7 days of administration in the first stage and 14 days of administration in the second stage
- clinical laboratory tests :blood biochemistryTime frame: followed up for 28 days in the first stage and followed up for 14 days in the second stage
- clinical laboratory tests : urine routineTime frame: 7 days of administration in the first stage and 14 days of administration in the second stage
- clinical laboratory tests : urine routineTime frame: followed up for 28 days in the first stage and followed up for 14 days in the second stage
- clinical laboratory tests :blood coagulation functionTime frame: 7 days of administration in the first stage and 14 days of administration in the second stage
- clinical laboratory tests :blood coagulation functionTime frame: followed up for 28 days in the first stage and followed up for 14 days in the second stage
- 12-lead electrocardiogram (ECG)Time frame: 7 days of administration in the first stage and 14 days of administration in the second stage
- 12-lead electrocardiogram (ECG)Time frame: followed up for 28 days in the first stage and followed up for 14 days in the second stage
- All-cause mortalityTime frame: 28 days after completion of dosing in the third stage
- All-cause mortalityTime frame: 90 days after completion of dosing in the third stage
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Beijing You 'an Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Qingyuan People's Hospital (Sixth Affiliated Hospital of Guangzhou Medical University)
Qingyuan, Guangdong, China · Recruiting
Shiyan City Taihe Hospital
Shiyan, Hubei, China · Recruiting
Hunan Medical College General Hospital (formerly Huaihua City First People's Hospital)
Huaihua, Hunan, China · Recruiting
Pingxiang Second People's Hospital
Pingxiang, Jiangxi P, China · Recruiting
First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
The Affiliated Hospital of Binzhou Medical University
Binzhou, Shandong, China · Recruiting
Heze Municipal Hospital
Heze, Shandong, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.